-
B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.
JCI InsightLinsley PS, Greenbaum CJ, Speake C, Long SA, Dufort MJ -
Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype.
Clin ImmunolLord JD, Long SA, Shows DM, Thorpe J, Schwedhelm K, Chen J, Kita M, Buckner JH -
Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics.
Pediatr DiabetesWeir GC, Ehlers MR, Harris KM, Kanaparthi S, Long SA, Phippard D, Weiner LJ, Jepson B, McNamara JG, Koulmanda M, Strom TB, ITN RETAIN Study Team. -
Cytometry TOF identifies alveolar macrophage subtypes in acute respiratory distress syndrome.
JCI InsightMorrell ED, Wiedeman A, Long SA, Gharib SA, West TE, Skerrett SJ, Wurfel MM, Mikacenic C -
Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.
Cell ImmunolLong SA, Thorpe J, Herold KC, Ehlers M, Sanda S, Lim N, Linsley PS, Nepom GT, Harris KM -
Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state.
Clin ImmunolSchwedhelm K, Thorpe J, Murray SA, Gavin M, Speake C, Greenbaum C, Cerosaletti K, Buckner J, Long SA -
Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes.
Sci ImmunolLong SA, Thorpe J, DeBerg HA, Gersuk V, Eddy J, Harris KM, Ehlers M, Herold KC, Nepom GT, Linsley PS -
Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression.
Sci Transl MedHundhausen C, Roth A, Whalen E, Chen J, Schneider A, Long SA, Wei S, Rawlings R, Kinsman M, Evanko SP, Wight TN, Greenbaum CJ, Cerosaletti K, Buckner JH -
Type 1 diabetes immunotherapy using polyclonal regulatory T cells.
Sci Transl MedBluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q -
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
J Clin InvestRigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR -
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
J AutoimmunRosenzwajg M, Churlaud G, Mallone R, Six A, Dérian N, Chaara W, Lorenzon R, Long SA, Buckner JH, Afonso G, Pham HP, Hartemann A, Yu A, Pugliese A, Malek TR, Klatzmann D -
Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients.
PLoS OneCerosaletti K, Schneider A, Schwedhelm K, Frank I, Tatum M, Wei S, Whalen E, Greenbaum CJ, Kita M, Buckner JH, Long SA -
IL-2 therapy in type 1 diabetes: "Trials" and tribulations.
Clin ImmunolLong SA, Buckner JH, Greenbaum CJ -
Intersection between genetic polymorphisms and immune deviation in type 1 diabetes.
Curr Opin Endocrinol Diabetes ObesLong SA, Buckner JH -
Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes.
Clin Exp ImmunolBollyky JB, Long SA, Fitch M, Bollyky PL, Rieck M, Rogers R, Samuels PL, Sanda S, Buckner JH, Hellerstein MK, Greenbaum CJ
